Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.41 |
| ▸ | CHRNA1 | P02708 | 4/20 | 0.41 |
| ▸ | CHRNG | P07510 | 4/20 | 0.41 |
| ▸ | CHRNB1 | P11230 | 4/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.41 |
| ▸ | CHRND | Q07001 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16758861 | 0.73 | WDR91 (0.41) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL16771020 | 0.72 | CHRNA1 (0.35) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL17069186 | 0.72 | SLC6A3 (0.35) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL23532467 | 0.70 | SLC6A2 (0.46) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL23532468 | 0.70 | SLC6A2 (0.46) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL24269730 | 0.68 | EGLN2 (0.37) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL17177784 | 0.67 | CHRNB2 (0.37) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL16884630 | 0.67 | SLC6A2 (0.47) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL28198518 | 0.67 | CCR2 (0.42) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL17299186 | 0.67 | OPRM1 (0.36) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9694002-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9546164-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2015-09-10 | — | — | US | disclosed |
| WO-2015078374-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, RRM1 | SLC6A2 1679/4885SLC6A3 2186/4885CHRNA1 1737/4885 |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | C1R, SRR, PNISR | SLC6A2 927/4885SLC6A3 828/4885CHRNA1 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.